Topics

Glioblastoma | Treatment | Targeted therapy | Atezolizumab

Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Atezolizumab

Weathers SP, Li X, Zhu H, Damania AV, Knafl M, McKinley B, Lin H, Harrison RA, Majd NK, O'Brien BJ, Penas-Prado M, Loghin M, Kamiya-Matsuoka C, Yung WKA, Solis Soto LM, Maru DM, Wistuba I, Parra Cuentas ER, Hernandez S, Futreal A, Wargo JA, Schulze K, Darbonne WC, Ajami NJ, Woodman SE, de Groot JF.
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial.
Nat Commun. 2025 Apr 27;16(1):3950. doi: 10.1038/s41467-025-56930-7. PMID: 40289138. Interventional study. ˍ